rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NKTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow
      Nov 14Seeking AlphaNKTX
      Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications
      Nov 11BenzingaNKTX
      Nkarta reports safety data for autoimmune cell therapy NKX019
      Nov 11Investing.comNKTX
      Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
      Nov 11Yahoo FinanceNKTX
      Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials
      Nov 9Yahoo FinanceNKTX
      Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
      Nov 9Yahoo FinanceNKTX
      12 Health Care Stocks Moving In Friday's After-Market Session
      Nov 6BenzingaKPTINKTX
      Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
      Nov 6Yahoo FinanceNKTX
      Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 5Yahoo FinanceNKTX
      Stifel reiterates Buy rating on Nkarta stock, cites trial progress
      Sep 28Investing.comNKTX
      Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

      Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogenei

      Sep 27Yahoo FinanceNKTX
      Nkarta at stifel forum: safer cell therapy push gains traction
      Sep 23Investing.comNKTXSF
      H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)

      Detailed price information for Nkarta Inc (NKTX-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailNKTX
      Nkarta at H.C. Wainwright conference: autoimmune push gains focus
      Sep 16Investing.comNKTX
      Nkarta to Participate in September Investor Conferences
      Sep 10Yahoo FinanceNKTX
      Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

      Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster presentation highlighting NKX019’s clinical activity in systemic sclerosis SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di

      Sep 8Yahoo FinanceNKTX
      Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
      Sep 3Seeking AlphaNKTX

      This is the newest page. Registered accounts read further back.